Novartis today announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses with ...
US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the US ...
studies were published in Nature Medicine. Following the CHMP’s recommendation for approval, the European Commission (EC) is expected to issue a final decision within approximately two months. About ...
- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism designed ...
New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous urticaria (CSU) to be presented Long-term Cosentyx® data build on extensive body of evidence ...
Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer The lead asset, SNV4818, ...
Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring importance of early ...
Site to serve patients in Southern US and add network capacity as RLT expands into earlier treatment lines and additional tumor types Company broke ground on 4 new manufacturing and R&D facilities, ...
Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented Phase II data evaluating safety and efficacy results of remibrutinib for treatment of peanut ...
February 19, 2026 – Novartis AG has notified the Board of Novartis India Limited (“NIL”), a company listed on BSE Limited, that Novartis AG has entered into an agreement with the ChrysCapital group ...
) is a global, randomized, multicenter, double-blind, placebo-controlled Phase III clinical trial comparing the efficacy and safety of Vanrafia versus placebo in patients with IgAN at risk of ...
Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1 Distinction expedites development and review of treatments for serious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results